Mrna treatment for treatment-resistant autoimmune diseases
Part of Immune system & allergy clinical trials.
This study tests a new mRNA treatment that targets CD19, a protein on some immune cells that cause autoimmune diseases. It aims to help people with severe or treatment-resistant autoimmune diseases like immune thrombocytopenia, autoimmune hemolytic anemia, lupus, or scleroderma, where the immune system attacks the body's own tissues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have a severe or hard-to-treat autoimmune disease such as immune thrombocytopenia, autoimmune hemolytic anemia, lupus, or scleroderma.
- You are able to care for yourself and are expected to live more than 6 months.
- You are not pregnant, breastfeeding, or planning to get pregnant, and you agree to use reliable birth control if needed.
- You do not have uncontrolled infections, recent cancer (except certain skin or cervix cancers), or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new kind of treatment called LNP-mRNA that targets specific cells involved in autoimmune diseases like lupus. It might help reset your immune system if standard treatments haven't worked.
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new treatment using your own immune cells, modified to target and calm the overactive immune system that causes autoimmune diseases. It may help reduce symptoms for conditions like lupus, scleroderma, and others.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
This study uses a patient's own immune cells, specially modified to target and reduce harmful immune cells that cause autoimmune diseases. It is for people with conditions like lupus, rheumatoid arthritis, or other listed autoimmune diseases that have not improved with standard treatments.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.